ASCO 2024: Lerociclib Plus Letrozole a Viable Treatment Option for HR-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Lerociclib significantly improved progression-free survival versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.